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Abstract 
 
Multiple myeloma remains a fatal plasma cell malignancy. However, new insights into the disease 
biology and immunology have identified molecular mechanisms, underling functional interactions 
between plasma cells and the bone marrow microenvironment that have become molecular targets 
of so-called “new drugs” such as thalidomide, lenalidomide, and bortezomib. Recently, the 
combinations of new drugs with melphalan and prednisone in elderly patients, and with autologous 
stem cell transplantation in induction and/or maintenance schedules in younger patients have 
significantly prolonged overall survival. Optimal combinations and timing are a matter of debate. 
Moreover, management of side effects is a key clinical target to improve long-term quality of life. 
Many randomized phase III studies are currently in progress to address these issues. Whether these 
new advancements in myeloma treatment will eventually translate into a long chronic phase or a 
monoclonal gammopathy of undetermined significance–like status for the majority of patients 
remains, however, still unanswered. 
 
Introduction 
 
Multiple myeloma represents the second most common hematological malignancy worldwide and 
causes about 11,000 and 19,000 deaths every year in the United States and Europe, 
respectively.
1 and 2
 The introduction of “new drugs,” such as thalidomide, bortezomib, and 
lenalidomide has significantly improved overall response rates, progression-free survival, and 
overall survival.
3
 Relapsed patients rescued with these new drugs had longer survival from disease 
recurrence as compared with those who were not treated with these new therapies (30.9 versus 14.8 
months, P < .001). Moreover, in the past decade, newly diagnosed patients had a 50% improvement 
in overall survival as compared with those diagnosed before December 1996, when thalidomide was 
first introduced (44.8 versus 29.9 months, P < .001). 
3
 Allografting has been regarded as the only 
potentially curative treatment. 
4, 5 and 6
 However, the high transplant-related mortality greatly limited 
its use. 
7 and 8
 Reduced-intensity conditionings, where graft versus myeloma effects play a more 
important role than the intensity of the preparative regimen, have been explored. 
9, 10, 11 and 12
 
However, results from different groups are conflicting and allografting has become a less attractive 
option.
13, 14, 15 and 16
 Here we present a brief description of the three agents, thalidomide, 
lenalidomide and bortezomib, that dramatically changed the treatment paradigm of multiple 
myeloma treatment and focus on a sequential treatment strategy that may translate into high 
complete remission rates and prolonged overall survival. 
 
“New Drugs” and Their Mechanisms of Action 
 
Thalidomide and Immunomodulatory Drugs 
 
Initially, the anti-angiogenic characteristics of thalidomide and the correlation between bone 
marrow angiogenesis and disease activity formed the empirical basis for its clinical use of in 
refractory/relapsed myeloma. However, the evidence that bone marrow microvessel density were 
not significantly changed in responsive patients soon indicated that this drug is also endowed with 
other mechanisms of action. Thalidomide induces G1 growth arrest and apoptosis in myeloma cells 
and shows immune-modulatory effects by inducing CD3+ T-cell proliferation, secretion of 
interferon gamma (IFN-γ) and interleukin 2 (IL-2), and natural killer cell expansion that could 
trigger myeloma cell lysis.
17
 Importantly, thalidomide was soon shown to act in synergy with 
dexamethasone.
18
 The very first evidence of the clinical efficacy of thalidomide was in patients with 
heavily pretreated multiple myeloma (MM) refractory to conventional or high-dose chemotherapy. 
Singhal et al
19
 reported ≥ 25% reductions in serum or urine paraprotein levels in 32% of 84 patients. 
At the time of publication, side-effects included constipation, peripheral neuropathy, weakness, and 
morning somnolence whereas severe neutropenia was a rare event. This pioneering experience was 
later updated on a large series of patients and confirmed the encouraging data.
20
 
Thalidomide derivatives were later developed. Two major classes of chemical and functional 
analogues were developed and defined as selective cytokine inhibitory drugs and 
immunomodulatory drugs.
21
 Among these latter, CC-5013, or lenalidomide, was shown to be up to 
2000 times more potent in inducing T-cell proliferation and up to 100 times in enhancing IL-2 and 
IFN-γ secretion.22 Richardson et al initially reported a phase I study on 27 patients with relapsed or 
refractory myeloma. Lenalidomide was given at four daily doses: 5 mg, 10 mg, 25 mg, and 50 mg.
22
 
Grade 3 myelosuppression was seen in all patients treated with 50 mg, and 25 mg was then 
considered the maximal tolerated dose. A ≥ 25% paraprotein reduction was observed in 17 of 24 
patients. Importantly, most of them had received prior therapy with thalidomide. 
 
Proteosome Inhibitors 
 
Bortezomib is the prototype of proteasome inhibitors.
23
 Its molecular target is the 26S proteasome, a 
cytoplasm multisubunit protein complex which regulates the turnover of several intracellular 
proteins controlling fundamental cell functions such as cell cycle and apoptosis. Bortezomib shows 
high affinity and specificity for the catalytic activity of the 26S proteasome, the inhibition of which 
can block protein degradation. Nuclear factor κB (NF-κB) is a transcription factor bound to its 
inhibitory partner protein κB (IκB). Once IκB is phosphorylated in the cytoplasm is eventually 
degraded by the 26S proteasome complex with the release of NF-κB, that migrates into the cell 
nucleus and induces the synthesis of anti-apoptotic proteins. The biological NF-κB functions are 
blocked by the inhibition of IκB degradation within the proteosome complex which sequesters NF-
κB in the cytoplasm.24 and 25 Orlowski et al initially reported a phase I study on 27 patients with 
advanced hematological malignancies.
26
 Interestingly, 9 patients with advanced plasma cell 
disorders showed a response including a complete remission in a myeloma patient. Evidence of 
significant clinical activity was provided by Richardson et al in a phase II study of 202 heavily 
pretreated myeloma patients.
27
 Responses were seen in 67 patients, including 7 complete remissions 
with negative immunofixation. 
 
Toxicity Profiles 
 
Toxicity of new drugs represents a clinical challenge. Venous thromboembolism soon emerged as 
the most serious side effect of thalidomide in untreated newly diagnosed myeloma patients.
28
 Most 
thromboembolic episodes occurred early and distant from central venous catheters suggesting a 
systemic thalidomide-induced prothrombic state.
29
 However, no baseline prothrombotic laboratory 
abnormalities could be identified. Prophylaxis is now routinely administered in newly diagnosed 
patients.
30
 Other side effects, such as peripheral neuropathy, numbness, and paraesthesia appeared 
to correlate with drug dose and treatment duration and should promptly be recognized before 
neurological damage becomes irreversible. 
Lenalidomide has shown a safer toxicity profile.
31
 Myelosuppression may be a serious side effect 
requiring drug reduction or discontinuation. Every effort should be made to manage adverse events 
so that patients can remain on treatment to ensure the greatest treatment efficacy. Prolonged 
neutropenia can effectively be managed by dose modifications and addition of granulocyte–colony-
stimulating factor (G-CSF), whereas thromboembolic prophylaxis should be considered for all 
patients. 
Bortezomib-based regimens put patients at risk of peripheral neuropathy, which may be irreversible 
in a number of patients. In elderly patients, we reduced the incidence of peripheral neuropathy by 
about 70% by modifying the administration schedule of bortezomib from days 1, 4, 8, and 11 to 
days 1, 8, 15, and 22. This may be particularly effective for patients who have pre-existing 
neuropathy.
32 and 33
 
 
“New Drugs” In Young Patients 
 
Nowadays, the definition of a “young patient” is understood not only as patients who are younger 
than 60 to 65 years of age, but also as those who are older than 65 years but remain medically fit 
enough to endure intensive and repetitive treatments. After showing their efficacy in 
refractory/relapsed patients,
34, 35 and 36
 new drugs have extensively been used during the induction 
phase instead of the once standard vincristine-adriamycin-dexametasone (VAD)–based regimens, 
with the aim of increasing tumor cytoreduction and response rates before autologous 
transplantation. Most importantly, it is imperative to explore if the initial benefit of higher response 
rates will also translate into prolonged post-transplant overall survival. Results have so far been 
rather conflicting. 
Lokhorst et al showed a post-transplant benefit in progression-free survival of the combination of 
thalidomide-adriamycin-dexametasone versus VAD in those patients who reached a very good 
partial remission but not in those who reached a complete remission after induction. However, there 
was no difference in overall survival between the two cohorts.
37
 In contrast, Morgan et al reported a 
prolonged superior benefit in terms of complete remission post-transplant of a combination of 
cyclophosphamide-thalidomide-dexametasone over cyclophosphamide-VAD.
38
 
Lenalidomide with high-dose dexametasone has been shown to be active in newly diagnosed 
patients.
39
 Moreover, a recent randomized trial showed that lenalidomide with low-dose rather than 
high-dose dexametasone was associated with less toxicity and better overall survival.
40
 
The proteosome inhibitor bortezomib as single agent or in combination with dexametasone has 
shown potent activity in newly diagnosed myeloma. Harousseau et al compared bortezomib-
dexamethasone versus VAD.
41
 Both pre- and post-transplant very good partial response rates were 
superior with bortezomib-dexamethasone as compared to VAD (38% versus 15%, and 54% versus 
37%, respectively). However, the difference in progression-free survival did not reach statistical 
significance (36 versus 30 months, respectively). No overall survival benefit has been reported so 
far. The major adverse effect was the risk of neurotoxicity early in the disease course. Recent 
reports, however, show that reducing the dose of bortezomib to once weekly shows similar efficacy 
with significantly lower risk of neurotoxicity.
42
 
Multidrug combinations have also been explored. Bortezomib-thalidomide-dexamethasone resulted 
in better response rates and progression-free survival compared to thalidomide-dexametasone or 
bortezomib-dexametasone in randomized trials.
43 and 44
 Similarly, the combination of bortezomib-
lenalidomide-dexamethasone produce high overall and complete remission rates in newly diagnosed 
patients.
45
 Overall, three-drug combinations appear to improve response rates and progression-free 
survival compared to two-drug combinations. However, longer follow-up is needed to define if the 
addition of a third drug results in prolonged overall survival without affecting quality of life. 
 
“New Drugs” In Eldery and Medically Unfit Patients 
 
The oral combination melphalan-prednisone has been regarded as the standard of care for both 
elderly and medically unfit patients not eligible for autologous stem cell transplantation for decades. 
The introduction of immunomodulatory drugs and proteasome inhibitors has radically changed the 
treatment paradigm and led to new standards of care. To date, five randomized phase III clinical 
trials have compared melphalan-prednisone with the combination melphalan-prednisone-
thalidomide.
46, 47, 48, 49, 50 and 51
 All these studies showed a prolonged time-to-progression with the 
latter combination, although in only two this advantage also translated into an improved overall 
survival. In another trial, the combination of melphalan-prednisone with bortezomib was associated 
with an increased time-to-progression and overall survival as compared with melphalan-prednisone. 
Moreover, recent data showed the superiority of the four-drug combination melphalan-prednisone-
thalidomide-bortezomib followed by bortezomib-thalidomide maintenance over melphalan-
prednisone-bortezomib, and of melphalan-prednisone-lenalidomide followed by lenalidomide 
maintenance over melphalan-prednisone alone.
32 and 52
 Importantly, reports showed a reduced 
toxicity profile of lenalidomide when associated with low doses of steroids rather than the standard 
doses.
40
 The availability of different efficacious regimens may provide clinicians with the 
opportunity to tailor a specific approach for each patient in the light of comorbidities and biologic 
age. Moreover, regional differences in the choice of a given combination may be seen. The use of 
melphalan-prednisone in association with new drugs remains a predominantly European approach, 
whereas the use of lenalidomide with low-dose dexamethasone is more commonly used in North 
America.
40
 Both approaches appear to lead to similar clinical outcomes. 
 
Sequential Approaches for the Treatment of MM 
 
The recent development of new agents with potent antimyeloma activity that target not only 
malignant plasma cells but also the myeloma microenvironment has opened a new era of clinical 
research. However, it does not currently appear that any combinations of these new biologically 
based drugs allow physicians to reach a cure. Many trials are currently in progress to define the 
optimal combinations of new drugs with older agents, with/without autologous transplantation, that 
may provide long-term disease control and translate into significantly prolonged overall survival. 
Two main approaches may be investigated: one may be that of using three- or even four-drug 
combinations including novel potent antimyeloma agents in the upfront setting to maximize tumor 
reduction and the other that of using newer and older agents in a more sequential schedule with the 
goal of converting the disease into a chronic phase that prolongs survival and improves quality of 
life. 
Richardson et al recently reported the first prospective evaluation of a combination of lenalidomide-
bortezomib and dexametasone in previously untreated myeloma patients. In this phase I/II study, 
the maximum planned doses were first established as 25 mg for lenalidomide, 1.3 mg/m
2
 for 
bortezomib, and 20 mg for dexametasone. An impressive overall response rate of 100%, including 
high complete and very good partial remission rates, was reported.
53
 Furthermore, after a median 
follow-up of 21 months, estimated 18-month progression-free and overall survival for this novel 
combination with/without autologous transplantation were 75% and 97%, respectively. 
We recently evaluated the effect of sequential approaches in elderly patients and in those who were 
not eligible for autologous transplantation.
32 and 54
 We investigated the role of bortezomib as 
induction before autologous stem cell transplantation, followed by lenalidomide as consolidation-
maintenance in newly diagnosed elderly patients.
54
 One hundred two patients, 65- to 75-years old, 
were enrolled. Induction consisted of four 21-day cycles of bortezomib (1.3 mg/m
2
 days 1, 4, 8, 11), 
pegylated-liposomal-doxorubicin (30 mg/m
2
 day 4), and dexamethasone (40 mg/d: cycle 1, days 1–
4, 8–11, 15–18; cycles 2–4, days 1–4). Autologous stem cell transplantation included two 
procedures after melphalan 100 mg/m
2
 and G-CSF–mobilized stem-cell rescue. Consolidation 
included four 28-day cycles of lenalidomide (25 mg/d days 1–21 every 28 days) with prednisone 
(50 mg every other day), followed by maintenance with lenalidomide (10 mg/d days 1–21) until 
relapse. Primary endpoints were safety and efficacy. In a recent analysis, after induction, 58% of the 
patients obtained at least a very good partial response including a complete response rate of 13%. 
Importantly, immunofixation-negative complete remission rates gradually increased to 38% after 
the two autologous stem cell transplants and up to 66% after consolidation with the combination 
lenalidomide-prednisone and maintenance with lenalidomide alone. At a median follow-up of 21 
months, the 2-year progression-free survival and overall survival were 69%, and 86%, respectively. 
During the induction phase, transplant-related mortality was 3%. Severe grade 3–4 adverse events 
were thrombocytopenia, neutropenia, peripheral neuropathy, and pneumonia. During the 
consolidation-maintenance phase, adverse events included primarily neutropenia, 
thrombocytopenia, pneumonia, and cutaneous rash. To our knowledge, this has been the first 
sizeable phase II study conducted in newly diagnosed myeloma patients to evaluate the clinical 
effectiveness of a sequential treatment approach which included new agents with different 
mechanisms of actions. Bortezomib was used during induction to cyto-reduce the disease before a 
tandem autologous transplant; lenalidomide was then used to consolidate-maintain post-transplant 
response. This suggests that a sequential approach may be effective in gradually increasing response 
rates. Although the importance of “death of response” is not universally accepted, the achievement 
of higher complete remission or very good partial remission rates is associated with a strong 
positive impact on overall survival.
35
 
A bortezomib-based regimen was investigated in untreated elderly patients by the Spanish group.
42
 
Two hundred sixty patients were first randomly assigned to receive six cycles of bortezomib-
melphalan-prednisone or bortezomib-thalidomide-prednisone as induction therapy, and then 
randomly assigned to maintenance therapy with bortezomib-prednisone or bortezomib-thalidomide. 
The primary endpoint was response rate after induction and maintenance phases. Complete 
remission rates were 28% and 20% after induction, respectively, whereas the rates were 44% in the 
bortezomib-thalidomide group and 39% in the bortezomib-prednisone group after maintenance 
therapy. 
A phase III study on untreated patients ineligible for autologous transplantation by Palumbo et al 
compared the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-
thalidomide followed by maintenance with bortezomib-thalidomide with bortezomib-melphalan-
prednisone without maintenance.
32
 A total of 511 patients were randomized. The primary endpoint 
was progression-free survival. The 3-year estimates of progression-free survival were 56% in 
patients receiving the four-drug combination with maintenance and 41% in those receiving the 
three-drug combination without maintenance (P = .008). Complete response rates were 38% and 
24% (P < .001), respectively, whereas the 3-year overall survivals were comparable, at 89% and 
87% (P = .77), respectively. 
Two additional phase II studies in elderly patients that evaluated the clinical efficacy of melphalan 
plus prednisone combined with bortezomib or lenalidomide showed gradual disease responses; 30% 
of the treated patients achieved maximum monoclonal immunoglobulin reduction after 6 months of 
therapy. These data support treatment plans which include sequential exposure to different drugs to 
maximize depth of response.
52 and 55
 
The role of maintenance has also been explored in young patients undergoing autografting. 
Thalidomide alone or in combination with corticosteroids used as maintenance after autologous 
stem cell transplantation has shown promising results in three randomized studies.
56, 57 and 58
 In 
another study, maintenance with thalidomide improved progression-free survival but not overall 
survival.
59
 Long-term treatment with thalidomide and bortezomib inevitably increases the risk of 
peripheral neuropathy whereas lenalidomide appears more tolerated without the risk of cumulative 
toxicity. Finally, one study reported a significant increase in complete response rates with a 
sequential approach, which included consolidation with bortezomib and/or immunomodulatory 
drugs, although this increase was primarily seen in patients who reached at least a very good partial 
remission. Thus, consolidation may play its best role in responsive patients.
60
 
In summary, although randomized phase III trials comparing different induction and consolidation-
maintenance schemas are needed, in our view, the sequential use of new drugs in both young and 
elderly patients may represent an efficacious treatment paradigm to obtain high complete remission 
rates and prolonged response duration that may eventually translate into a significant overall 
survival advantage. 
Moreover, serious clinical challenges may lie ahead. MM has been associated with both solid 
tumors and hematological malignancies such as acute myeloid leukemia and myelodisplastic 
syndromes.
61
 Recently, preliminary data on phase III trials from the Intergroupe Francophone du 
Myelome, the Cancer and Leukemia Group B, and the Gruppo Italiano Malattie e Matologiche 
dell'Adulto Myeloma groups, reported a higher than expected incidence of hematological 
malignancies in the arms that included lenalidomide.
62, 63 and 64
 
Results are not conclusive, however, the incidence of secondary tumors should carefully be 
monitored during the long-term follow-up examinations. 
 
Conclusion 
 
During the past decade, the introduction of new agents with potent antimyeloma activity has 
changed the treatment paradigm for myeloma cases. A significant improvement in overall survival 
has undoubtedly been reported in many trials after the incorporation of new drugs as salvage 
therapy. However, a further overall survival advantage with the use of these agents with/without 
autologous transplantation as induction therapy remains to be determined in long-term prospective 
clinical trials. Moreover, some issues in the long-term toxicity management, including the potential 
emergence of secondary malignancies, of new agents need to be addressed. Sequential use of new 
therapies with maintenance may represent a novel approach for patients who have MM, and current 
evidence is moving clinical practice in this direction. The best clinical benefits of the several 
ongoing clinical trials should become apparent in the next few years. 
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